Latest / AI Investment Edge: Stocks, Markets & Money / EP 40 | RxSight Stock Analysis: Will a Cataract Breakthrough Make Investors Rich?
Transcript
- 0:00SPEAKER_00: Will a cataract breakthrough make investors rich?
- 0:02SPEAKER_01: That is the million dollar question, isn't it?
- 0:04SPEAKER_00: Right. I mean, imagine buying a pair of custom glasses,
- 0:07SPEAKER_00: but the prescription can be magically adjusted by a laser and Oh,
- 0:11SPEAKER_00: weeks after you actually start wearing them.
- 0:13SPEAKER_01: Which sounds like total science fiction.
- 0:15SPEAKER_00: It really does.
- 0:16SPEAKER_00: But that is the clinical magic Rx site is offering right now just, you know,
- 0:19SPEAKER_00: for cataract surgery.
- 0:21SPEAKER_00: And when we talk about medical technology in these deep dives,
- 0:24SPEAKER_00: it is so easy to get swept up in that kind of sci-fi brilliance.
- 0:27SPEAKER_01: Oh, absolutely. The tech is always the shiny object.
- 0:30SPEAKER_00: Yeah.
- 0:30SPEAKER_00: But today we are looking at whether that clinical ingenuity actually translates
- 0:34SPEAKER_00: into a durable business for you as an investor.
- 0:38SPEAKER_00: Because look, this isn't a story about waiting for a miraculous new FDA approval.
- 0:42SPEAKER_00: No, not at all.
- 0:43SPEAKER_00: And it's not a non-surgical cure that somehow replaces traditional surgery.
- 0:47SPEAKER_00: This technology is already sitting in clinics right now.
- 0:50SPEAKER_01: It's in the wild.
- 0:51SPEAKER_00: Exactly. It essentially allows eye doctors to refine the power
- 0:54SPEAKER_00: of an implanted artificial lens after the cataract surgery is entirely done
- 0:59SPEAKER_00: and the eye has healed.
- 1:01SPEAKER_01: Which is undeniably a massive leap forward for patient outcomes. Right.
- 1:05SPEAKER_01: But the core investment question we are testing today is
- 1:09SPEAKER_01: whether that post-surgery ingenuity can actually revive falling demand
- 1:13SPEAKER_01: for the company itself.
- 1:14SPEAKER_00: Because that's the real hurdle.
- 1:16SPEAKER_01: Yeah.
- 1:17SPEAKER_01: I mean, they have significant money in the bank,
- 1:19SPEAKER_01: which certainly buys their management team time.
- 1:22SPEAKER_01: But can they turn that borrowed time into repeat business,
- 1:25SPEAKER_01: like recurring profitable business from the clinics
- 1:29SPEAKER_01: that already have their equipment?
- 1:30SPEAKER_00: Right. That's the ultimate test.
- 1:32SPEAKER_01: Yeah.
- 1:32SPEAKER_00: And to figure out if they can actually pull that off,
- 1:34SPEAKER_00: we are unpacking the AI Investment Edge report from iPulse AI.
- 1:39SPEAKER_00: Yes, we are.
- 1:41SPEAKER_00: And the setup here is pretty compelling.
- 1:43SPEAKER_00: As of November 7th, the public weighted ratings are a strong buy for both the short
- 1:48SPEAKER_00: and long horizons, while the separate platform action is strong buy and keep.
- 1:54SPEAKER_01: Okay, we really need to frame those ratings properly before we go any further.
- 1:58SPEAKER_00: Let's do it.
- 1:59SPEAKER_01: Because those labels, they represent a research thesis for us to test today.
- 2:03SPEAKER_00: Right, not a guarantee.
- 2:05SPEAKER_01: Exactly.
- 2:05SPEAKER_01: They are not a conclusion that having cash automatically makes the share price safe.
- 2:10SPEAKER_01: A strong buy rating frames a very specific, demanding path to success.
- 2:16SPEAKER_00: Okay, so let's actually visualize that path,
- 2:18SPEAKER_00: starting with the product and the friction that's holding it back.
- 2:22SPEAKER_01: Good place to start.
- 2:23SPEAKER_00: So RxSight sells a premium artificial lens implanted during surgery,
- 2:27SPEAKER_00: plus the special light delivery equipment used to adjust it later.
- 2:31SPEAKER_00: I like to think of it kind of like a tailor making final adjustments.
- 2:35SPEAKER_01: Oh, that's a good analogy.
- 2:36SPEAKER_00: Right. Like you buy a custom suit, but the tailor doesn't finish the hem or take
- 2:41SPEAKER_00: in the waste until after the fabric settles on your exact frame for a few weeks.
- 2:44SPEAKER_01: Right. They need to see how it fits first.
- 2:46SPEAKER_00: Exactly.
- 2:47SPEAKER_00: The simple clinical explanation here is that doctors use controlled UV light
- 2:51SPEAKER_00: to adjust the implanted lens.
- 2:53SPEAKER_01: Yeah, that's the core mechanism.
- 2:54SPEAKER_00: But, and this is the big but, I want to neutrally point out the friction here.
- 3:00SPEAKER_00: Patients have specific eyewear requirements,
- 3:02SPEAKER_00: they have to wear special UV blocking glasses,
- 3:05SPEAKER_00: and they have to commit to extra visits to the clinic.
- 3:07SPEAKER_01: Which adds so much practical work.
- 3:09SPEAKER_00: Right, for busy clinics.
- 3:11SPEAKER_01: Yeah, that workflow friction is the absolute heart of the financial narrative.
- 3:15SPEAKER_01: I mean, going back to the tailor for three separate things is annoying.
- 3:19SPEAKER_01: But making a patient come back to a clinic for multiple light adjustments,
- 3:22SPEAKER_00: It's a huge commitment.
- 3:23SPEAKER_01: It's a massive logistical headache for a busy eye doctor.
- 3:27SPEAKER_01: And transitioning to the financials,
- 3:29SPEAKER_01: the released financial synthesis emphasizes
- 3:32SPEAKER_01: that the repeat lens economics should be great.
- 3:35SPEAKER_00: In theory.
- 3:36SPEAKER_01: Right.
- 3:37SPEAKER_00: Right.
- 3:37SPEAKER_01: High margins, liquidity, modest physical capital requirements.
- 3:41SPEAKER_01: But their newer third quarter results, the ones released November 3rd,
- 3:45SPEAKER_01: put all of that under severe pressure.
- 3:48SPEAKER_00: Yeah. Let's look at finding one, the revenue and the trend.
- 3:52SPEAKER_00: All right.
- 3:53SPEAKER_01: It's rough.
- 3:54SPEAKER_00: Yeah.
- 3:55SPEAKER_01: Quarterly revenue is roughly 25 million, which is down 19 percent.
- 3:59SPEAKER_01: And they posted a like a 16 million dollar loss.
- 4:02SPEAKER_00: OK, let's unpack this because there's a weird contradiction here.
- 4:07SPEAKER_00: So lens volume fell about 11 percent, but their device count actually grew.
- 4:12SPEAKER_01: Right.
- 4:13SPEAKER_00: So wait, is this this does this mean individual clinics are just doing fewer fewer procedures?
- 4:19SPEAKER_01: Well, so we have to be careful there.
- 4:21SPEAKER_01: That is an aggregate measure, right?
- 4:23SPEAKER_01: It's not a same clinic utilization report.
- 4:26SPEAKER_00: Okay, so it's the whole network combined.
- 4:29SPEAKER_01: Exactly. Recovering use in their existing accounts is the future test.
- 4:33SPEAKER_01: Also, regarding that loss, a loss is a loss.
- 4:35SPEAKER_01: Partner payments don't magically make it recurring profitability.
- 4:39SPEAKER_00: Right, which brings us to finding two, their margins.
- 4:43SPEAKER_00: Product margin recovered to roughly 74% versus roughly 71% previous.
- 4:49SPEAKER_00: But that still remained below the roughly 80% we saw a year ago.
- 4:53SPEAKER_01: And we should clarify, this product margin is cleaner
- 4:56SPEAKER_01: than their previous corporate margins that included licensing.
- 4:59SPEAKER_00: Right.
- 4:59SPEAKER_01: But it was weighed down by inventory reserves and higher costs.
- 5:03SPEAKER_01: Plus, you have to remember that a high product gross margin can totally coexist
- 5:08SPEAKER_01: with an overall loss.
- 5:09SPEAKER_00: When R&D eats it all up.
- 5:11SPEAKER_01: Exactly. When support and R&D exceed your gross profit.
- 5:15SPEAKER_00: So finding three, the balance sheet.
- 5:17SPEAKER_00: This is their safety net.
- 5:18SPEAKER_01: Supposedly, yeah.
- 5:20SPEAKER_00: They highlighted September cash and short-term investments of $255 million,
- 5:25SPEAKER_00: but that includes $60 million they already received from Alcon.
- 5:28SPEAKER_01: Right. That's a big chunk.
- 5:30SPEAKER_00: And if you do the math, that implies a dated equity value of roughly $190 million,
- 5:35SPEAKER_00: factoring in Friday's share price and the September share count.
- 5:38SPEAKER_01: Which is fascinating, but I have to remind everyone,
- 5:41SPEAKER_01: this liquidity isn't a protected stock price floor.
- 5:44SPEAKER_00: Why not?
- 5:45SPEAKER_01: Because there are leases, there are ongoing losses, and there's potential dilution.
- 5:50SPEAKER_01: Cash gives them runway.
- 5:51SPEAKER_01: It doesn't guarantee a floor.
- 5:53SPEAKER_00: Good point. And finding four really shows where that cash is going.
- 5:57SPEAKER_00: Their nine-month physical capex was just $4 million. Wow. Right?
- 6:01SPEAKER_00: Compared to roughly $28 million in operating R&D.
- 6:04SPEAKER_01: Yeah, because low plant spending doesn't mean commercial and development execution is cheap.
- 6:09SPEAKER_01: Building a sales force and doing research is expensive.
- 6:12SPEAKER_00: It really is.
- 6:13SPEAKER_00: So let's walk through the specific cash bridge for the first nine months of 2026.
- 6:18SPEAKER_01: Yeah, let's do the arithmetic here.
- 6:19SPEAKER_01: Operating cash flow was roughly $25 million positive.
- 6:22SPEAKER_00: Which sounds amazing until you look closer.
- 6:25SPEAKER_01: Right, because that includes the $60 million Alcon receipt.
- 6:28SPEAKER_00: Okay.
- 6:28SPEAKER_01: Subtracting just that receipt leaves $35 million of company-wide operating outflow
- 6:33SPEAKER_01: before the $4 million capex.
- 6:35SPEAKER_00: Got it.
- 6:35SPEAKER_01: Which leads to roughly $39 million in outflow after.
- 6:39SPEAKER_00: I need to emphasize this heavily to you listening.
- 6:42SPEAKER_00: This is only historical period arithmetic.
- 6:44SPEAKER_01: Yes, absolutely.
- 6:45SPEAKER_00: It is not a recurring rate.
- 6:47SPEAKER_00: It is not a forecast runway.
- 6:48SPEAKER_00: And other working capital and collaboration effects still remain.
- 6:52SPEAKER_01: Totally. So let's shift to the price reference for a second.
- 6:55SPEAKER_00: Yeah. The reference is the Friday, November 6th close of about $4.50 per share.
- 7:00SPEAKER_01: Right.
- 7:00SPEAKER_01: And what's fascinating here is how the forecasts lay out the evidence-weighted base path.
- 7:05SPEAKER_00: Okay. What does that path look like?
- 7:07SPEAKER_01: It implies a cumulative price gain of about 56% to September 2027.
- 7:12SPEAKER_00: Okay. Okay.
- 7:13SPEAKER_01: And 270% to September 2031.
- 7:16SPEAKER_00: Wow, that's huge.
- 7:17SPEAKER_01: It is. But remember, these are fixed original dates, not rolling annual clocks.
- 7:22SPEAKER_01: And there is absolutely no dividend cash assumed in these models.
- 7:26SPEAKER_00: Makes sense.
- 7:27SPEAKER_00: So let's break down the three scenarios driving those numbers, base, bull and bear.
- 7:30SPEAKER_01: Sure.
- 7:31SPEAKER_00: The base scenario is pretty straightforward.
- 7:33SPEAKER_00: Repeat demand recovery and cost leverage.
- 7:35SPEAKER_01: Basically, they figure it out and scale efficiently.
- 7:38SPEAKER_00: Right.
- 7:38SPEAKER_00: And the bull case is faster adoption and successful development and collaboration.
- 7:43SPEAKER_00: But what about the bear case?
- 7:44SPEAKER_00: Like what happens if things just go wrong?
- 7:47SPEAKER_01: The bear case is bleak.
- 7:48SPEAKER_01: It describes a lasting low volume niche where rival lenses offer easier workflows.
- 7:54SPEAKER_00: So doctors just switch to the easier option.
- 7:56SPEAKER_01: Exactly.
- 7:57SPEAKER_01: And in that scenario, the sales force costs drastically outpaced delivery.
- 8:01SPEAKER_01: And that massive cash pile just erodes.
- 8:04SPEAKER_00: Yikes.
- 8:05SPEAKER_01: And I have to warn you, actual business failure could be significantly worse
- 8:08SPEAKER_01: than an optimistic model's bear case.
- 8:11SPEAKER_00: A sobering thought.
- 8:12SPEAKER_00: So let's map out the four quadrants here, the drivers versus the frictions.
- 8:16SPEAKER_01: Let's do it.
- 8:17SPEAKER_00: For drivers, we've got repeat demand, post-surgery differentiation,
- 8:21SPEAKER_00: and obviously Alcon's funding.
- 8:23SPEAKER_01: Yeah, those are the tailwinds.
- 8:25SPEAKER_00: But the frictions are heavy, extra visits, eyewear compliance, practice budgets,
- 8:30SPEAKER_00: and rival bundling.
- 8:32SPEAKER_00: Just having your equipment in a clinic doesn't make that clinic a captive customer.
- 8:36SPEAKER_01: No, doctors will abandon it if it slows them down.
- 8:39SPEAKER_00: Exactly. And what about the extreme ends, the tails?
- 8:42SPEAKER_01: So for the upside tails, you're looking at things like a strategic acquisition,
- 8:47SPEAKER_01: or maybe they develop a simpler next-generation workflow?
- 8:50SPEAKER_00: Like a single-visit adjustment.
- 8:52SPEAKER_01: Right. But we need to clarify that these are purely hypothetical.
- 8:55SPEAKER_01: There is no announced single visit product today.
- 8:58SPEAKER_00: Okay. And the downside tail?
- 9:00SPEAKER_01: That would be a major development or regulatory failure. Again, hypothetical.
- 9:04SPEAKER_01: There is no actual safety recall happening.
- 9:06SPEAKER_00: Good to know.
- 9:07SPEAKER_00: Now, I want to bring up the Alcon refund expiry because this is tricky accounting.
- 9:11SPEAKER_01: Oh, yeah.
- 9:12SPEAKER_00: The $50 million part of the upfront payment actually became non-refundable on October 28th.
- 9:18SPEAKER_01: Correct.
- 9:19SPEAKER_00: Since it was already Q3 cash, how does that work in Q4?
- 9:22SPEAKER_01: So Q4 transaction price allocation includes both point-in-time licenses
- 9:27SPEAKER_01: and development over time.
- 9:29SPEAKER_00: Okay.
- 9:30SPEAKER_01: There was no exact split claimed yet between those two.
- 9:32SPEAKER_01: Plus, later development and contract risks still exist,
- 9:36SPEAKER_01: completely separate from this refund expiry.
- 9:38SPEAKER_00: Got it.
- 9:39SPEAKER_00: So that brings us to the alpha gap.
- 9:41SPEAKER_01: Right. The core gap in how this is being valued.
- 9:45SPEAKER_01: The market is pricing this as a permanent technological failure due
- 9:48SPEAKER_01: to weak equipment placements.
- 9:49SPEAKER_00: Because the aggregate numbers look bad.
- 9:51SPEAKER_01: Exactly.
- 9:52SPEAKER_01: But the research points out that the business could still earn repeat revenue
- 9:56SPEAKER_01: through the existing clinics they're already in.
- 9:58SPEAKER_00: Okay, but here's where it gets really interesting.
- 10:00SPEAKER_00: The strongest counterpoint is that lens volumes actually fell too.
- 10:04SPEAKER_01: Yes.
- 10:04SPEAKER_00: Like cash buys the management time to fix their process,
- 10:07SPEAKER_00: but it can't magically make clinics want that process if demand is inherently weak.
- 10:12SPEAKER_01: And that tension right there is the source of a very real advisor disagreement in the data.
- 10:16SPEAKER_00: How so?
- 10:17SPEAKER_01: Well, the research draws from 14 contributions, three models, and nine analytical archetypes.
- 10:22SPEAKER_00: And just a reminder, these are analytical frameworks, not independent humans arguing in a room.
- 10:28SPEAKER_01: Right. But there's a huge debate among those models.
- 10:31SPEAKER_01: You have a skeptical high-weight perspective
- 10:33SPEAKER_01: that entirely excludes future Alcon royalties and worries heavily
- 10:37SPEAKER_01: about models dilution.
- 10:38SPEAKER_00: Versus the optimists.
- 10:40SPEAKER_01: Yeah.
- 10:40SPEAKER_01: The optimists who foresee earlier self-funding through those high-margin repeat economics.
- 10:46SPEAKER_00: It's like, okay, it's like hiring expanded staff for a restaurant before the customers arrive.
- 10:50SPEAKER_01: That's a great way to look at it.
- 10:51SPEAKER_00: Right.
- 10:52SPEAKER_00: It might improve account support or it might just raise costs before demand ever follows.
- 10:57SPEAKER_00: The ultimate test is recurring lens growth versus the cost of that support.
- 11:01SPEAKER_01: Absolutely. So we have to watch the quarterly catalysts to see which way it breaks.
- 11:06SPEAKER_00: And the research has 20 steps, right?
- 11:08SPEAKER_01: Yes.
- 11:09SPEAKER_01: And while all 20 model steps are positive, a smooth modeled line isn't a stock guarantee.
- 11:15SPEAKER_00: No, never.
- 11:16SPEAKER_00: So what's the timeline we should be watching?
- 11:18SPEAKER_01: In Q4 2026, watch for fresh lens orders.
- 11:22SPEAKER_01: That is a test of organic demand, not just the Alcon accounting shift.
- 11:26SPEAKER_00: Okay, fresh orders.
- 11:28SPEAKER_00: What about 2027?
- 11:29SPEAKER_01: First half 2027, you want to watch for guidance support, training, and utilization.
- 11:35SPEAKER_00: And the back half?
- 11:36SPEAKER_01: By Q3 2027, the base path needs solid evidence of demand stabilization.
- 11:42SPEAKER_00: Makes sense.
- 11:42SPEAKER_01: Then 2028 and 2029 depend on development and narrowing cash consumption.
- 11:48SPEAKER_01: And finally, 2030 and 2031 depend on commercialization and durable cash.
- 11:53SPEAKER_00: Just to be clear for you listening, these are research assumptions, right?
- 11:57SPEAKER_00: Not company launch dates.
- 11:58SPEAKER_01: Correct. These are modeled milestones.
- 12:01SPEAKER_00: Speaking of milestones, let's talk about the future Alcon money.
- 12:05SPEAKER_00: There's up to 140 million extra in conditional milestones.
- 12:10SPEAKER_01: Yes, with 60 already received, like we mentioned.
- 12:12SPEAKER_00: And what about the royalties?
- 12:14SPEAKER_01: So that is a 30% royalty, but it is only on net sales of future collaboration products.
- 12:20SPEAKER_01: It is totally distinct from today's ordinary lens revenue.
- 12:23SPEAKER_00: Okay, that's a crucial distinction.
- 12:24SPEAKER_00: Now let's look at the timeline of how this research shifted because things change fast.
- 12:29SPEAKER_01: Very fast.
- 12:30SPEAKER_00: We have two baselines.
- 12:32SPEAKER_00: The July 5th baseline had 12 contributions, one model, and eight archetypes.
- 12:36SPEAKER_01: Right.
- 12:36SPEAKER_00: Versus the September baseline, which jumped to 14 contributions, three models,
- 12:41SPEAKER_00: and nine archetypes.
- 12:42SPEAKER_01: The business delta there was very genuine.
- 12:45SPEAKER_00: What actually happened in that window?
- 12:47SPEAKER_01: Well, the Alcon deal became public on July 6th.
- 12:50SPEAKER_01: The new CEO started in July and then guidance was withdrawn in August.
- 12:55SPEAKER_00: Wow.
- 12:55SPEAKER_01: And all of that was before the September research.
- 12:59SPEAKER_01: The October refund expiry and November's weak demand came even later.
- 13:02SPEAKER_00: That is a lot of turbulence.
- 13:05SPEAKER_01: It naturally connects to some of our past deep dies.
- 13:07SPEAKER_00: Oh, definitely. Like our last public stock was PepsiCo in episode 39.
- 13:12SPEAKER_00: And that really highlights how medical device adoption differs
- 13:15SPEAKER_00: from established consumer economics.
- 13:17SPEAKER_01: It's a completely different beast.
- 13:19SPEAKER_00: Completely.
- 13:20SPEAKER_00: It also reminds me of our earlier Boston Scientific conversation where we looked
- 13:23SPEAKER_00: at adoption and repeat demand.
- 13:25SPEAKER_01: Yeah, that's a perfect parallel for the clinic friction here.
- 13:29SPEAKER_00: Or Medtronic for device economics and execution.
- 13:32SPEAKER_00: And of course, our GSK deep dive looking
- 13:34SPEAKER_00: at development milestones versus actual cash generation.
- 13:37SPEAKER_01: All of those highlight how fragile these adoption curves can be in health care.
- 13:41SPEAKER_00: Right. So pulling this all together, what does this all mean if it goes wrong?
- 13:45SPEAKER_00: What breaks the thesis?
- 13:47SPEAKER_01: The invalidation points are pretty clear.
- 13:49SPEAKER_01: If recurring lens demand keeps falling,
- 13:52SPEAKER_01: margins deteriorate and operating cash consumption remains high.
- 13:56SPEAKER_00: That breaks it.
- 13:56SPEAKER_01: It completely breaks the base path.
- 13:58SPEAKER_01: Also, if the partnership fails, it removes the collaboration upside leg.
- 14:02SPEAKER_00: Though the existing lens franchise remains separate, right?
- 14:05SPEAKER_01: It does, yes.
- 14:06SPEAKER_01: But I have to firmly remind you there is no cash floor here and there is no guaranteed buyout.
- 14:11SPEAKER_00: It's all on execution.
- 14:13SPEAKER_01: Completely.
- 14:14SPEAKER_00: Well, to synthesize this whole deep dive, these strong buy ratings rest on demanding conditions.
- 14:19SPEAKER_00: You have abundant dated liquidity, but weak current demand and a totally unproven turnaround.
- 14:26SPEAKER_00: The case absolutely needs repeat demand and company cash generation to improve.
- 14:31SPEAKER_00: For the bigger picture, visit iPulse AI to explore our complete rankings
- 14:34SPEAKER_00: of covered assets, discover the strongest buys,
- 14:37SPEAKER_00: and see the research behind the ratings all in one place.
- 14:40SPEAKER_00: Primary research conducted through the iPulse AI platform by Future Edge Group.
- 14:44SPEAKER_00: If this conversation helped, Please like, leave a comment, and subscribe.
- 14:48SPEAKER_00: We are publishing a new podcast every day of the week except Thursday.
- 14:51SPEAKER_00: Stay tuned for the next podcast on new holdings.
- 14:55SPEAKER_00: NewBank's digital banking model offers a very different test
- 14:58SPEAKER_00: of scaling customer relationships into earnings.